Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients

NCT06066957 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Cytomegalovirus Infections
Transplant-Related Disorder

Interventions

DRUG: Letermovir 480 MG [Prevymis]

Sponsor

University of Pennsylvania

Collaborators

[object Object]